A new treatment for allergic and atopic dermatitis

Feature
Video

How Zenrelia is helping to treat common skin conditions in canines.

Sponsored by Elanco

Adam Christman, DVM, MBA spoke with Andrew Rosenberg, DVM, DACVD about how Zenrelia is a JAK inhibitor designed to disrupt cytokine signaling pathways that trigger itch and inflammation related to canine allergic and atopic dermatitis.

Learn More About:

  • How Zenrelia shows visible improvements in allergic itch within just one day
  • Optimized dosing options
  • The continuous efficacy of Zenrelia and its ability to relieve long-term itch

DISCLAIMER

Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-1649

INDICATIONS

Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

IMPORTANT SAFETY INFORMATION

Read the entire package insert before using this drug, including the Boxed Warning.

For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia

WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

© 2025 MJH Life Sciences

All rights reserved.